Adenovirus Infection In Animals

Animals have tested positive for unsuspected natural infection with lipogenic adenoviruses. Methods for testing animals, including food stuffs and experimental animals, for lipogenic adenovirus infection are disclosed. Exposure to infected meat and animal co-products may cause health and safety issues. As a result of lipogenic adenovirus infection in experimental animal species, research related to fat or glucose metabolism, energy metabolism, cancer biology, and obesity research may have been or may be negatively affected or compromised.

Method For Detecting Lipogenic Adenovirus

An immunoassay methods, immunoassay kits, and immunoassay devices for detecting lipogenic adenovirus infection in a subject. The immunoassay method includes using an antibody capture polypeptide, an antibody detection polypeptide, and optionally a competitor polypeptide. 1. A method of detecting lipogenic adenovirus infection in a sample , said method comprising the steps of:(a) providing a solid support coated with a first antibody capture polypeptide comprising at least 100 amino acids of an adenovirus type-36 (Ad-36) fiber coat protein, wherein the polypeptide does not include SEQ ID NO: 1;(b) contacting the sample to the antibody capture polypeptide such that anti-antibody capture polypeptide antibodies, if present in the sample, bind to the antibody capture polypeptide to form an antibody capture polypeptide-anti-antibody capture polypeptide antibody complex;(c) contacting the complex, if present, with an antibody detecting polypeptide comprising the at least 100 amino acids of the Ad-36 fiber coat protein; and(d) detecting the presence, absence, or quantity of specific binding of the detection polypeptide to the complex, thereby detecting a lipogenic adenovirus infection in the sample.2. The method of claim 1 , further comprising the step of applying the first antibody capture polypeptide comprising at least 100 amino acids of an adenovirus type-36 (Ad-36) fiber coat protein claim 1 , wherein the polypeptide does not include SEQ ID NO: 1 to the solid support for a period of time to allow the first antibody capture polypeptide to adhere to a surface of the solid support.3. The method of claim 1 , wherein the antibody capture polypeptide and/or the antibody detecting polypeptide comprises or consists of SEQ ID NO:10.4. The method of claim 1 , wherein the antibody capture polypeptide comprises a non-adenovirus heterologous amino acid sequence and step (c) further comprises contacting the sample with a competitor polypeptide comprising the heterologous amino acid ...

Methods And Compositions For Treatment Of Lipogenic Virus Related Conditions

Disclosed are methods of treatment for adipogenic virus-related conditions. The methods may comprise administering a composition comprising an effective dose of an antiviral agent to a subject having an adipogenic adenovirus-related condition. Administration of the antiviral agent may prevent or reduce viral proliferation in the subject. The method may also include administering a composition comprising an effective dose of a therapeutic agent known to treat the adipogenic adenovirus-related condition in conjunction with the composition comprising an effective dose of an antiviral agent. Administration of the antiviral agent and the therapeutic agent may reduce or eliminate one or more symptoms of the adipogenic adenovirus-related condition more efficiently than administration of either the antiviral agent and the therapeutic agent alone. 1. A method for treating a lipogenic adenovirus-related condition comprising:a) identifying a subject infected with a lipogenic adenovirus and having a lipogenic adenovirus-related condition; andb) administering a composition comprising an effective dose of an antiviral agent to the subject thereby preventing or reducing lipogenic adenovirus proliferation and/or action or thereby reducing or eliminating one or more symptoms of the lipogenic adenovirus-related condition.2. The method of 1 , further comprising administering a composition comprising an effective dose of a therapeutic agent known to treat the lipogenic adenovirus-related condition in conjunction with the composition comprising an effective dose of an antiviral agent , wherein administration of the antiviral agent and the therapeutic agent reduce or eliminate one or more symptoms of the lipogenic adenovirus-related condition more efficiently than administration of either the antiviral agent or the therapeutic agent alone.3. The method of claim 1 , wherein the step of identifying a subject having a lipogenic adenovirus-related condition comprises at least one of:(i) ...

Adipogenic Adenoviruses as a Biomarker for Disease

A vaccine composition may be administered to a subject to increase immunity to an adipogenic adenovirus-related cancer. The vaccine composition stimulates the production of adipogenic adenovirus neutralizing antibodies in the subject, which may increase immunity to the adipogenic adenovirus-related cancer in the subject. 1. A method of increasing immunity to an adipogenic adenovirus-related cancer in a subject , said method comprising the steps of:administering a vaccine composition including a pharmaceutically effective dose of an active ingredient selected from the group consisting of a killed adenovirus type 36, an inactivated adenovirus type 36, a protein or peptide sequence encoding an adenovirus type 36 coat protein or fragment thereof, and an adenovirus type 36 E1A protein, to the subject; andstimulating the production of adipogenic adenovirus neutralizing antibodies in the subject such that the adipogenic adenovirus neutralizing antibodies increase immunity to the adipogenic adenovirus-related cancer in the subject.2. The method of claim 1 , wherein the vaccine composition in said administering step is administered one or more of intranasally claim 1 , orally claim 1 , intravenously claim 1 , intramuscularly claim 1 , subcutaneously claim 1 , and peritoneally.3. The method of claim 1 , wherein the subject is a human.4. The method of claim 1 , wherein the subject is a non-human animal.5. The method of claim 1 , wherein the administration of the vaccine composition is a primary vaccination.6. The method of claim 5 , further comprising the step of administering at least one booster vaccination after the primary vaccination to maintain protective immunity against adipogenic adenovirus in the vaccinated subject.7. The method of claim 1 , wherein the active ingredient has a concentration in the range of about 1 ng/ml to about 1 mg/ml.8. The method of claim 1 , wherein the vaccine composition is a solution having a volume in the range of about 0.1 ml to about 10 ml ...

Adipogenic adenoviruses as a biomarker for disease

Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes

Infection with obesifying adenoviruses in animals and humans may be used to predict changes in body weight and disease status. More particularly, infection with certain adenoviruses, such as adenovirus type 36 (Ad-36) and adenovirus type 37 (Ad-37) may cause removal of the normal equilibrium factors that control fat cell metabolism and may make individuals more responsive than normal individuals to perturbations, which cause body composition change including weight gain or weight loss.

Methods and compositions for treatment of lipogenic virus related conditions

Disclosed are methods of treatment for adipogenic virus-related conditions. The methods may comprise administering a composition comprising an effective dose of an antiviral agent to a subject having an adipogenic adenovirus-related condition. Administration of the antiviral agent may prevent or reduce viral proliferation in the subject. The method may also include administering a composition comprising an effective dose of a therapeutic agent known to treat the adipogenic adenovirus-related condition in conjunction with the composition comprising an effective dose of an antiviral agent. Administration of the antiviral agent and the therapeutic agent may reduce or eliminate one or more symptoms of the adipogenic adenovirus-related condition more efficiently than administration of either the antiviral agent and the therapeutic agent alone.

Viral obesity methods and compositions

Methods and compositions for diagnosing whether obesity in a human is caused by a virus (AD-36) or whether a person is susceptible to becoming obese because of having been infected with an obesity-causing virus are disclosed. Further disclosed are methods for testing or screening bodily fluids for the presence of obesity-causing viruses, methods for treating and preventing viral obesity in humans, methods for preparing vaccine compositions for treating and preventing viral obesity in humans, such as vaccine compositions themselves, and viruses which cause viral obesity in humans.

Machinery guards

Adipogenic Adenoviruses As A Biomarker For Disease

A vaccine composition may be administered to a subject to increase immunity to an adipogenic adenovirus-related cancer. The vaccine composition stimulates the production of adipogenic adenovirus neutralizing antibodies in the subject, which may increase immunity to the adipogenic adenovirus-related cancer in the subject.

Adipogenic adenoviruses as a biomarker for disease.

Esta invención se refiere a la relación entre infección con adenovirus adipogénico, tal como adenovirus-36 (Ad-36) y las etiologías de obesidad y cánceres relacionados con obesidad y otras enfermedades. Adicionalmente, la invención se refiere a ensayar a un sujeto por el estado de Ad-36 y utilizar el estado Ad-36 como un marcador por la presencia de cáncer, para pronosticar el riesgo futuro de desarrollar cánceres tales como cáncer de mama y próstata y/o para pronosticar la agresividad y pronóstico de estos cánceres.

Viral obesity methods and compositions

Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy

Lipogenic adenoviruses may serve as a biomarker for the identification of the development of abnormal adipose tissue hypertrophy. A diagnostic test may be used to identify abnormal adipose tissue hypertrophy in subjects associated with lipogenic adenovirus infection.

Endless tracks for self-laying track type vehicles

Spreaders for manures, fertilisers or the like

Bearing assemblies and machinery guards incorporating them